PHV-wordings
Here you will find safety-relevant information that must be implemented in the corresponding product information due to a PHV (pharmacovigilance) issues.
Due to the relaunch of the EMA website in December 2023, you will find the current links to the entries prior to December 01, 2023 at https://www.ema.europa.eu
Search narrowed by
Venlafaxine
PSUR-outcome
|
17/03/2023
Further information and amendments to the product information in all EU languages are available on the EMA website.
Amikacin
PSUR-outcome
|
17/03/2023
Further information and amendments to the product information in all EU languages are available on the EMA website.
Bemiparin
PSUR-outcome
|
17/03/2023
Further information and amendments to the product information in all EU languages are available on the EMA website.
Esomeprazole/Naproxen
PSUR-outcome
|
16/03/2023
Further information and amendments to the product information in all EU languages are available on the EMA website.
Levomethadone
PSUR-outcome
|
16/03/2023
Further information and amendments to the product information in all EU languages are available on the EMA website.
Methadone
PSUR-outcome
|
16/03/2023
Further information and amendments to the product information in all EU languages are available on the EMA website.
Zonisamide
PSUR-outcome
|
27/02/2023
Further information can be found in the Commission Decision and its annexes, which are available in all EU languages on the European Commission's (EC) website.
Lamivudine / Tenofovir disoproxil
PSUR-outcome
|
20/02/2023
Further information and amendments to the product information in all EU languages are available on the EMA website.
Ivermectin (systemic use)
PSUR-outcome
|
20/02/2023
Further information and amendments to the product information in all EU languages are available on the EMA website.
Cefuroxime sodium (except for intracameral use)
PSUR-outcome
|
20/02/2023
Further information and amendments to the product information in all EU languages are available on the EMA website.
